Daiwa Securities Group
VERV

Daiwa Securities Group’s Verve Therapeutics VERV Stock Holding History

Daiwa Securities Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-321
Closed -$4K – 1378
2025
Q2 		$4K Sell
321
-10,189
-97% -$58.1K ﹤0.01% 1181
2025
Q1 		$48K Sell
10,510
-376
-3% -$2.52K ﹤0.01% 1024
2024
Q4 		$61K Sell
10,886
-740
-6% -$4.17K ﹤0.01% 1044
2024
Q3 		$56K Sell
11,626
-468
-4% -$2.72K ﹤0.01% 1059
2024
Q2 		$59K Buy
12,094
+5,723
+90% +$36K ﹤0.01% 1087
2024
Q1 		$85K Sell
6,371
-401
-6% -$5.32K ﹤0.01% 1061
2023
Q4 		$94K Buy
6,772
+1,759
+35% +$21.8K ﹤0.01% 1021
2023
Q3 		$66K Hold
5,013
– – ﹤0.01% 1046
2023
Q2 		$94K Buy
5,013
+4,792
+2,168% +$79.8K ﹤0.01% 1018
2023
Q1 		$3K Hold
221
– – ﹤0.01% 1197
2022
Q4 		$4K Hold
221
– – ﹤0.01% 1172
2022
Q3 		$8K Buy
221
+80
+57% +$2.55K ﹤0.01% 1141
2022
Q2 		$2K Hold
141
– – ﹤0.01% 1258
2022
Q1 		$3K Hold
141
– – ﹤0.01% 1232
2021
Q4 		$5K Buy
+141
New +$5.92K ﹤0.01% 1205

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Daiwa Securities Group's VERV Position: Q3 2025 in Review

Daiwa Securities Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 321 shares — an estimated $4K sold.

Daiwa Securities Group first reported a position in VERV in Q4 2021 and held it in 15 quarters. The position peaked at $94K in Q4 2023. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Daiwa Securities Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Daiwa Securities Group sold 321 Verve Therapeutics shares in Q3 2025, an estimated $4K.
  • Daiwa Securities Group first reported a position in Verve Therapeutics in Q4 2021 and held it in 15 quarters.
  • Daiwa Securities Group's Verve Therapeutics position peaked at $94K in Q4 2023.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Daiwa Securities Group's 13F filing for Q3 2025, filed 14 Nov 2025.